Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation

被引:19
作者
Sahin, Ugur [1 ]
Dalva, Klara [1 ]
Gungor, Funda [1 ]
Ustun, Celalettin [2 ]
Beksac, Meral [1 ]
机构
[1] Ankara Univ, Cebeci Hosp, Dept Hematol, Fac Med, TR-06220 Ankara, Turkey
[2] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA
关键词
Stemcell transplantation; Relapse; GvHD; Myeloid leukemia; KIR; BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; LIGAND INCOMPATIBILITY; INTERNATIONAL BLOOD; INHIBITORY KIR; SURVIVAL; MISMATCH; ALLOREACTIVITY;
D O I
10.1007/s00277-018-3274-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Impact of donor-recipient killer immunoglobulin-like receptor (KIR) gene-gene matching on transplant outcomes is still inconclusive. Recent data suggest that killer cell immunoglobulin-like receptor (KIR) regulated natural killer cell (NK cell) activity may contribute to graft versus leukemia (GvL) effects and graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This case-control study aims to evaluate the effects of both aKIR and iKIR donor-recipient genotype matching on the outcomes of T cell replete HLA-identical sibling allo-HSCTs in a homogenous young patient population with myeloid leukemias. Five transplant outcomes including relapse rate (RR), disease-free survival (DFS), overall survival (OS), cumulative incidences of acute GvHD (aGvHD), and chronic GvHD (cGvHD) are investigated. Out of 96 HLA-identical sibling donor-recipient pairs, 34 were matched for activating KIR (aKIR), 38 for inhibitory KIR (iKIR), and 20 for both aKIR and iKIR. Fourty-four pairs were mismatched for both iKIR and aKIR. In univariate analysis, aKIR-matching resulted with a decrease in relapse rate (RR) (hazard ratio [HR]: 0.4; p = 0.04) and an increase in disease-free survival (DFS) (HR: 0.5; p = 0.03). In addition, cGvHD ocurred less frequently in the aKIR-matched (odds ratio [OR]: 0.4; p = 0.04) or iKIR-matched (OR: 0.3; p = 0.009) cohorts. Matching for both aKIR and iKIR was also associated with a decrease in cGvHD incidence (OR: 0.3; p = 0.02). iKIR-matching had no effects on RR, OS, or DFS. Analysis of donor haplotype effects showed haplotype-BB to have a tendency towards reduced relapse rate (HR: 0.4; p = 0.08) and better OS (HR: 0.4; p = 0.04); haplotype-Bx to increase the incidence of cGvHD (OR: 4.1; p = 0.03). In multivariate analysis, DFS advantage remained significant for aKIR-matching (HR: 0.5; p = 0.04); cGvHD incidence was reduced in the presence of iKIR-match (OR: 0.3; p = 0.02) and increased in the presence of haplotype-AB and -BB donors (OR: 7.9; p = 0.02; OR: 5.1; p = 0.03, respectively). In an attempt to investigate the pathogenesis underlying KIR-matching, we searched for residual NK/T cells on day 0 peripheral blood samples of six additional recipients and noted the presence of CD3(+) (7.0-91.4 x 10(6)/L) and CD56(+)57(+) (0.8-12.7 x 10(6)/L) cells. In conclusion, conditioning regimen surviving recipient NK/T cells potentially influenced by KIR-matching may contribute to GvL/GvH reactions.
引用
收藏
页码:1027 / 1039
页数:13
相关论文
共 47 条
[1]   Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation [J].
Bachanova, Veronika ;
Weisdorf, Daniel J. ;
Wang, Tao ;
Marsh, Steven G. E. ;
Trachtenberg, Elizabeth ;
Haagenson, Michael D. ;
Spellman, Stephen R. ;
Ladner, Martha ;
Guethlein, Lisbeth A. ;
Parham, Peter ;
Miller, Jeffrey S. ;
Cooley, Sarah A. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (09) :1602-1607
[2]   Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias [J].
Beelen, DW ;
Ottinger, HD ;
Ferencik, S ;
Elmaagacli, AH ;
Peceny, R ;
Trenschel, R ;
Grosse-Wilde, H .
BLOOD, 2005, 105 (06) :2594-2600
[3]   Impact of "Killer Immunoglobulin-Like Receptor/Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival [J].
Beksac, Kemal ;
Beksac, Meral ;
Dalva, Klara ;
Karaagaoglu, Ergun ;
Tirnaksiz, M. Bulent .
PLOS ONE, 2015, 10 (07)
[4]   Role of Killer Immunoglobulin-Like Receptor and Ligand Matching in Donor Selection [J].
Beksac, Meral ;
Dalva, Klara .
BONE MARROW RESEARCH, 2012,
[5]   The beneficial role of inhibitory KIR genes of HLA class INK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD [J].
Bishara, A ;
De Santis, D ;
Witt, CC ;
Brautbar, C ;
Christiansen, FT ;
Or, R ;
Nagler, A ;
Slavin, S .
TISSUE ANTIGENS, 2004, 63 (03) :204-211
[6]   NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation [J].
Bjorklund, Andreas T. ;
Schaffer, Marie ;
Fauriat, Cyril ;
Ringden, Olle ;
Remberger, Mats ;
Hammarstedt, Christina ;
Barrett, A. John ;
Ljungman, Per ;
Ljunggren, Hans-Gustaf ;
Malmberg, Karl-Johan .
BLOOD, 2010, 115 (13) :2686-2694
[7]   Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity [J].
Brunstein, Claudio G. ;
Wagner, John E. ;
Weisdorf, Daniel J. ;
Cooley, Sarah ;
Noreen, Harriet ;
Barker, Juliet N. ;
DeFor, Todd ;
Verneris, Michael R. ;
Blazar, Bruce R. ;
Miller, Jeffrey S. .
BLOOD, 2009, 113 (22) :5628-5634
[8]   Purposeful selection of variables in logistic regression [J].
Bursac, Zoran ;
Gauss, C. Heath ;
Williams, David Keith ;
Hosmer, David W. .
SOURCE CODE FOR BIOLOGY AND MEDICINE, 2008, 3 (01)
[9]   Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems:: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study [J].
Cahn, JY ;
Klein, JP ;
Lee, SJ ;
Milpied, N ;
Blaise, D ;
Antin, JH ;
Leblond, V ;
Ifrah, N ;
Jouet, JP ;
Loberiza, F ;
Ringden, O ;
Barrett, AJ ;
Horowitz, MM ;
Socié, G .
BLOOD, 2005, 106 (04) :1495-1500
[10]   The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia [J].
Cook, MA ;
Milligan, DW ;
Fegan, CD ;
Darbyshire, PJ ;
Mahendra, P ;
Craddock, CF ;
Moss, PAH ;
Briggs, DC .
BLOOD, 2004, 103 (04) :1521-1526